Your body is accumulating cells that refuse to die but have stopped doing their job. They sit in your tissues, leaking inflammatory compounds into the surrounding environment, damaging neighboring healthy cells, and contributing to the chronic inflammation that drives age-related disease. Researchers call them senescent cells. The popular term — zombie cells — is surprisingly accurate.
Senolytics are compounds designed to selectively eliminate these cells. The field is roughly a decade old, the human data is still thin, and the supplements marketed as senolytics range from genuinely promising to pure speculation. Here's what the evidence actually supports.
What Are Senescent Cells?
Every cell in your body has a lifecycle. It divides, performs its function, and eventually either divides again or undergoes programmed cell death (apoptosis). Senescent cells break this cycle — they've stopped dividing but resist the signals that would normally trigger their death.
Cellular senescence isn't inherently bad. It serves important functions:
Tumor suppression: When a cell accumulates DNA damage that could lead to cancer, senescence stops it from dividing. This is a critical anti-cancer defense mechanism, especially in younger bodies.
Wound healing: Senescent cells temporarily appear at wound sites, where they secrete growth factors that help tissue repair. Once healing is complete, the immune system normally clears them.
Embryonic development: Senescence plays a role in shaping tissues during development.
The problem emerges with age. As the immune system declines, it becomes less efficient at clearing senescent cells. They accumulate. And unlike quiet, dormant cells, senescent cells are actively harmful.
The SASP Problem
Senescent cells secrete a cocktail of inflammatory cytokines, growth factors, and proteases collectively called the senescence-associated secretory phenotype (SASP). This secretome includes IL-6, IL-8, TNF-alpha, MMP-3, and dozens of other pro-inflammatory molecules.
The SASP does measurable damage:
- Chronic inflammation: SASP compounds contribute to the persistent low-grade inflammation ("inflammaging") that underlies cardiovascular disease, type 2 diabetes, and neurodegeneration
- Tissue dysfunction: SASP signals can impair stem cell function and tissue regeneration in surrounding healthy tissue
- Senescence spreading: Some SASP factors can induce senescence in neighboring cells, creating a cascade effect
- Immune evasion: Ironically, SASP compounds can modify the local immune environment to protect senescent cells from clearance
By some estimates, senescent cells make up only 1-5% of total cells in aged tissues, but their disproportionate inflammatory output means they may drive a significant fraction of age-related dysfunction. Removing a small number of cells could theoretically have outsized effects.
Related: Understanding senescent cell biology pairs well with Anti-Aging Supplements Ranked by Research and Biological Age Testing: Which Predicts Lifespan?.
The Pioneer Senolytic: Dasatinib + Quercetin
The foundational senolytic combination was identified by James Kirkland's group at the Mayo Clinic in 2015. Their approach was systematic: senescent cells rely on specific anti-apoptotic pathways (BCL-2 family, PI3K/AKT, p53/p21) to survive. Find compounds that disable those survival pathways, and senescent cells lose their resistance to death while healthy cells — which don't depend on the same pathways — survive.
Dasatinib is an FDA-approved tyrosine kinase inhibitor used in leukemia treatment. It targets several kinases that senescent cells rely on for survival, particularly in fat tissue progenitors.
Quercetin is a naturally occurring flavonoid found in onions, apples, and berries. It acts on different anti-apoptotic pathways, particularly in endothelial cells and bone marrow stem cells.
The combination works because different cell types rely on different survival pathways. Dasatinib and quercetin together cover more senescent cell types than either alone.
Human Evidence for D+Q
The first human pilot study (Hickson et al., 2019, published in EBioMedicine) tested dasatinib + quercetin in 14 patients with idiopathic pulmonary fibrosis — a disease with known senescent cell involvement. Three days of D+Q (100 mg dasatinib + 1000 mg quercetin daily) improved 6-minute walk distance and several measures of physical function. Senescent cell markers decreased in skin biopsies.
A follow-up study in diabetic kidney disease patients (2020, also from the Kirkland group) showed reduced senescent cell burden in adipose tissue and skin after a brief D+Q regimen.
These are small, open-label studies without placebo controls. They establish feasibility and suggest biological activity, but they do not prove clinical efficacy. Larger controlled trials are underway.
Dasatinib is a prescription chemotherapy drug with significant side effects including fluid retention, bleeding risk, and cardiac toxicity. It should never be self-administered for longevity purposes without physician oversight and monitoring. The quercetin component alone is available over the counter, but the combination requires medical supervision.
Fisetin: The Over-the-Counter Candidate
Fisetin is a flavonoid found in strawberries, apples, persimmons, and several other fruits and vegetables. It emerged as a senolytic candidate after a 2018 study from the Kirkland lab showed that fisetin reduced senescent cell markers and extended lifespan in aged mice when given late in life.
The appeal of fisetin over D+Q is accessibility — fisetin is available as an over-the-counter supplement, doesn't require a prescription, and has a favorable safety profile based on available data.
What the Research Shows
Mouse data (2018): High-dose fisetin (100 mg/kg, equivalent to roughly 500 mg/kg in human dose conversion) reduced senescent cell markers in multiple tissues and extended median and maximum lifespan in mice when started at the equivalent of human late middle age.
Cell culture data: Fisetin demonstrates senolytic activity in human cell culture models, particularly in human umbilical vein endothelial cells (HUVECs) and human fat cell progenitors.
Human trials: The AFFIRM trial (Allergy, Immunology, and Fisetin to Reduce Markers of aging) at the Mayo Clinic has been evaluating fisetin in humans. Early data suggests fisetin is well tolerated, but definitive efficacy data from controlled trials has not yet been published as of early 2026.
Practical Considerations for Fisetin
Dosing uncertainty: The mouse studies used very high doses. Typical supplement doses (100-500 mg daily) may not achieve the tissue concentrations needed for senolytic effects. Some protocols use intermittent high-dose regimens (1-2 grams for 2 consecutive days, repeated monthly), attempting to mimic the hit-and-run approach used in mouse studies.
Bioavailability: Fisetin has poor oral bioavailability. Some supplement manufacturers use liposomal or lipid-based formulations to improve absorption, but these haven't been validated in senolytic-specific contexts.
Timing: If fisetin works as a senolytic (which remains unproven in humans), intermittent high-dose pulses are more theoretically sound than daily low-dose supplementation. Senolytics should kill senescent cells and then be cleared — chronic exposure is unnecessary and could have unintended effects.
Harvard-Mayo Safety Study
The collaboration between Harvard Medical School researchers and the Mayo Clinic's Kirkland group produced critical safety data for the senolytic field. Their work established several important principles:
Intermittent dosing is key. Senolytic compounds don't need to be taken continuously. A brief treatment (1-3 days) can clear senescent cells, and because senescent cells accumulate slowly, treatments can be spaced weeks to months apart. This dramatically reduces cumulative drug exposure and side effect risk.
Tissue specificity matters. Different senolytic compounds clear senescent cells in different tissues. D+Q is effective in fat and vascular tissue. Fisetin may have different tissue preferences. A one-size-fits-all approach may miss significant senescent cell populations.
Monitoring is feasible. The studies demonstrated that senescent cell burden can be measured (via skin biopsies, blood biomarkers like p16INK4a, and SASP markers) before and after treatment, enabling objective assessment of whether a senolytic intervention worked.
Age-dependent response. The research suggests that senolytic interventions may be most beneficial in older individuals with higher baseline senescent cell burdens. In younger, healthier individuals, the senescent cell load may be too low for clearance to produce measurable benefits.
Alzheimer's Pilot Data
One of the most compelling applications of senolytics is in neurodegenerative disease. Senescent cells accumulate in the brain with age and are found at elevated levels in Alzheimer's disease tissue.
A pilot study using dasatinib + quercetin in Alzheimer's patients (published in Nature Medicine, 2023) demonstrated that:
- D+Q crosses the blood-brain barrier at sufficient concentrations
- Senescent cell markers decreased in cerebrospinal fluid after treatment
- The treatment was tolerable in this older, cognitively impaired population
This was a safety and feasibility study — it was not designed to demonstrate cognitive improvement. But the fact that senolytics reached the brain and reduced senescent markers there opens a new avenue for Alzheimer's research that bypasses the amyloid hypothesis that has dominated (and largely failed to produce treatments) for decades.
Senolytic therapy for neurodegeneration is in its earliest stages. The pilot data is encouraging from a mechanistic standpoint, but no cognitive benefits have been demonstrated in controlled human trials. This is a space to watch, not a space to self-medicate.
The Supplement Market vs. the Science
The senolytic supplement market has exploded. Products labeled "senolytic" or "zombie cell cleanser" now fill online stores. Most contain some combination of quercetin, fisetin, and other flavonoids.
A reality check on what's being sold:
Quercetin alone has limited senolytic evidence as a standalone. The Kirkland research used it in combination with dasatinib. Quercetin supplements at standard doses (500-1000 mg daily) may have general anti-inflammatory benefits, but calling them "senolytic" stretches the evidence.
Fisetin supplements are more promising but face the bioavailability and dosing challenges mentioned above. Whether a 100 mg fisetin capsule taken daily achieves anything resembling the senolytic effects seen in mouse studies is genuinely unknown.
Proprietary blends containing multiple flavonoids, curcumin, piperdine, and other compounds marketed as "senolytic stacks" have essentially zero direct evidence for senescent cell clearance.
What's reasonable: If you want to experiment with the most evidence-backed over-the-counter senolytic approach, intermittent high-dose fisetin (1-2 grams for 2 consecutive days monthly) is the closest to what the research protocols use. Track any changes with before-and-after blood work, including inflammatory markers like hsCRP and IL-6.
Where the Field Is Heading
Senolytic research is moving toward three key developments:
-
Better biomarkers: Currently, measuring senescent cell burden requires tissue biopsies. Blood-based biomarkers (p16INK4a, certain SASP components) are being validated to enable non-invasive monitoring.
-
Targeted senolytics: Next-generation compounds that target specific senescent cell types in specific tissues, reducing off-target effects and improving efficacy.
-
Combination approaches: Using senolytics alongside other longevity interventions — exercise (which has natural senolytic effects), rapamycin (which suppresses SASP), and NAD+ precursors (which may support cellular repair after senescent cell clearance).
The field is real science with a genuine mechanistic foundation. But the gap between the published research and what's available to consumers remains enormous. Most people buying "senolytic supplements" today are purchasing hope with a thin evidence wrapper.
Be the first to try Prova
We're building an app to track whether senolytic supplement tracking and biomarker monitoring actually works. Join the waitlist.